{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-J220C6L4/7ecf6696-aad3-4d51-b433-ce68b0dbd118/HTML","dcterms:extent":"37 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-J220C6L4/53d0e924-40c6-4bd4-83e9-2de88c519d39/PDF","dcterms:extent":"87 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-J220C6L4/72878761-eba3-42ab-afda-f116bbb68c83/TEXT","dcterms:extent":"30 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-J220C6L4","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2006","dc:creator":"Roškar, Robert","dc:format":[{"@xml:lang":"sl","#text":"številka:4"},{"@xml:lang":"sl","#text":"letnik:57"},{"@xml:lang":"sl","#text":"7 strani"},{"@xml:lang":"sl","#text":"str. 251-257"}],"dc:identifier":["ISSN:0014-8229","COBISSID:1975153","URN:URN:NBN:SI:doc-J220C6L4"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"antidepresivi"},{"@xml:lang":"en","#text":"drug"},{"@xml:lang":"sl","#text":"interakcije"},{"@xml:lang":"sl","#text":"zdravila"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Interakcije med zdravili za zdravljenje depresivne motnje in drugimi zdravili|"},"dc:description":[{"@xml:lang":"sl","#text":"Adverse interaction between antidepressants and other drugs are described in this article. Tricyclic antidepressants and selective serotonine reuptake inhibitors (SSRI) are frequently involved in serious drug interactions. Pharmacokinetic interactions based on drug metabolism occur most often for SSRI. Especially fluvoxamine and fluoxetine are highly potent inhibitors of multiple cytochrome P450 enzymes, which are also important metabolic pathways for many other drugs. Serious adverse effects (serotonin syndrome) based on pharmacodynamic interacions may also occur if a serotonin agonist is coadministrated with SSRI. For tricyclic antidepressants are characteristic pharmacodynamic interactions, but also pharmacokinetic interactions with otherdrugs are clinically important. The herb St Johnćs wort (Hypericum perforatum), which has also an antidepressive effect, interacts with many other drugs"},{"@xml:lang":"sl","#text":"V prispevku so opisane neželene interakcije med antidepresivi in drugimi zdravili. V interakcije z resnimi kliničnimi posledicami pogosto vstopata dve skupini: selektivni zaviralci ponovnega privzema serotonina in triciklični antidepresivi. Pri selektivnih zaviralcih ponovnega privzema serotonina (zlasti fluoksetin in fluvoksamin) prevladujejo farmakokinetične interakcije na osnovi metabolizma. Zavirajo namreč aktivnost citokromnih P450 encimov, ki so pomembna pot metabolizma številnih drugih učinkovin. Do resnih neželenih učinkov vključno s serotoninskim sindromom lahko pride tudi ob souporabi zdravil, ki imajo agonističen učinek na serotoninski sistem. Pri tricikličnih antidepresivih so zaradi neselektivnega delovanja pogoste farmakodinamične interakcije. Pomembne so tudi interakcije na nivoju metabolizma, rezultat pa je ponavadi višja plazemska koncentracija tricikličnih antidepresivov. Tudi rastlinski pripravek šentjanževka (Hypericum perforatum), ki ima dokazan antidepresiven učinek, pogosto vstopa v interakcije z drugimi zdravili"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-J220C6L4","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-J220C6L4"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-J220C6L4/53d0e924-40c6-4bd4-83e9-2de88c519d39/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-J220C6L4/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-J220C6L4"}}}}